Hansa Biopharma Q3 update: Modest progress ahead of 2024
Research Update
2023-10-27
07:04
Redeye updates its outlook on Hansa Biopharma, anticipating a gradually improving launch support ahead and supporting pipeline progress over the next 12 months. We make a negative revision reflecting the slow launch progress and a more stretched funding outlook. Our Base Case is SEK100 (175) with a Bull Case of SEK200 (400) and a Bear Case of SEK15 (45).
JU
Johan Unnerus
Disclosures and disclaimers